Eszopiclone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Eszopiclone" in English language version.

refsWebsite

Global rank English rank

26nih.gov

4^th place

16doi.org

2^nd place

6web.archive.org

1^st place

4europa.eu

68^th place

117^th place

3semanticscholar.org

11^th place

8^th place

2clincalc.com

3,912^th place

2,496^th place

2fda.gov

447^th place

338^th place

1in.gov.br

3,151^st place

5,932^nd place

1drugs.com

399^th place

333^rd place

1fadavis.com

low place

1cbsnews.com

108^th place

80^th place

1archive.today

14^th place

1escholarship.org

1,523^rd place

976^th place

1rxlist.com

7,927^th place

6,815^th place

1harvard.edu

18^th place

17^th place

1nationalarchives.gov.uk

744^th place

547^th place

1mhra.gov.uk

low place

1benzo.org.uk

low place

1gsk.com

low place

1twobirds.com

low place

1clinicaltrialsarena.com

low place

archive.today

"Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone)". European Medicines Agency. 15 June 2009. Archived from the original on 3 August 2012. Retrieved 7 April 2019.

benzo.org.uk

Ashton CH (April 2007). "Benzodiazepine Equivalence Table". benzo.org.uk. Retrieved 21 March 2008.

cbsnews.com

Edwards J (13 June 2009). "End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight". www.cbsnews.com. Retrieved 7 April 2019.

clincalc.com

"The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
"Eszopiclone - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

clinicaltrialsarena.com

"Almorexant for Treatment of Primary Insomnia". Clinical Trials Arena. Retrieved 2021-08-04.

doi.org

Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (December 2012). "Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration". BMJ. 345: e8343. doi:10.1136/bmj.e8343. PMC 3544552. PMID 23248080.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Tariq SH, Pulisetty S (February 2008). "Pharmacotherapy for insomnia". Clinics in Geriatric Medicine. 24 (1): 93–105, vii. doi:10.1016/j.cger.2007.08.009. PMID 18035234.
American Geriatrics Society 2015 Beers Criteria Update Expert Panel (November 2015). "American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults". Journal of the American Geriatrics Society. 63 (11): 2227–2246. doi:10.1111/jgs.13702. PMID 26446832. S2CID 38797655.{{cite journal}}: CS1 maint: numeric names: authors list (link)
Bain KT (June 2006). "Management of chronic insomnia in elderly persons". The American Journal of Geriatric Pharmacotherapy. 4 (2): 168–192. doi:10.1016/j.amjopharm.2006.06.006. PMID 16860264.
Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE (August 2009). "Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem". Journal of Clinical Sleep Medicine. 5 (4): 377–383. doi:10.5664/jcsm.27552. PMC 2725260. PMID 19968019.
Kripke DF (February 2016). "Mortality Risk of Hypnotics: Strengths and Limits of Evidence" (PDF). Drug Safety. 39 (2): 93–107. doi:10.1007/s40264-015-0362-0. PMID 26563222. S2CID 7946506.
Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE (August 2009). "Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem". Journal of Clinical Sleep Medicine. 5 (4): 377–383. doi:10.5664/jcsm.27552. PMC 2725260. PMID 19968019.
Brielmaier BD (January 2006). "Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent". Proceedings. 19 (1): 54–59. doi:10.1080/08998280.2006.11928127. PMC 1325284. PMID 16424933.
Forrester MB (October 2007). "Eszopiclone ingestions reported to Texas poison control centers, 2005 2006". Human & Experimental Toxicology. 26 (10): 795–800. Bibcode:2007HETox..26..795F. doi:10.1177/0960327107084045. PMID 18025051. S2CID 25102558.
Halas CJ (January 2006). "Eszopiclone". American Journal of Health-System Pharmacy. 63 (1): 41–48. doi:10.2146/ajhp050357. PMID 16373464.
Najib J (April 2006). "Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia". Clinical Therapeutics. 28 (4): 491–516. doi:10.1016/j.clinthera.2006.04.014. PMID 16750462.
Morinan A, Keaney F (December 2010). "Long-term misuse of zopiclone in an alcohol dependent woman with a history of anorexia nervosa: a case report". Journal of Medical Case Reports. 4 (1): 403. doi:10.1186/1752-1947-4-403. PMC 3014964. PMID 21143957.
Schwartz LM, Woloshin S (October 2009). "Lost in transmission--FDA drug information that never reaches clinicians". The New England Journal of Medicine. 361 (18): 1717–1720. doi:10.1056/NEJMp0907708. PMID 19846841.

drugs.com

"Eszopiclone Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 6 April 2019.

escholarship.org

Kripke DF (February 2016). "Mortality Risk of Hypnotics: Strengths and Limits of Evidence" (PDF). Drug Safety. 39 (2): 93–107. doi:10.1007/s40264-015-0362-0. PMID 26563222. S2CID 7946506.

europa.eu

ema.europa.eu

"Lunivia: Withdrawn application". European Medicines Agency. 17 September 2018. Retrieved 19 February 2023.
"Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone)". European Medicines Agency. 15 June 2009. Archived from the original on 3 August 2012. Retrieved 7 April 2019.
Committee for Medicinal Products for Human Use – Summary of Positive Opinion for Lunivia^{[permanent dead link]} – European Medicines Agency/Committee for Medicinal Products for Human Use, 23 Oct 2010
"Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone)". European Medicines Agency. 15 May 2009. Archived from the original on 1 December 2017.

fadavis.com

davisplus.fadavis.com

"Eszopiclone" (PDF). F.A. Davis. 2017. Archived from the original (PDF) on October 8, 2017. Retrieved April 15, 2017.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

fda.gov

"FDA warns of next-day impairment with sleep aid Lunesta". U.S. Food and Drug Administration (FDA). 15 January 2016. Retrieved 7 July 2023.

gsk.com

"GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia". Archived from the original on December 27, 2010.

harvard.edu

ui.adsabs.harvard.edu

Forrester MB (October 2007). "Eszopiclone ingestions reported to Texas poison control centers, 2005 2006". Human & Experimental Toxicology. 26 (10): 795–800. Bibcode:2007HETox..26..795F. doi:10.1177/0960327107084045. PMID 18025051. S2CID 25102558.

in.gov.br

Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

mhra.gov.uk

"Zopiclone overdose". MHRA. Medicines and Healthcare Products Regulatory Agency. Archived from the original on December 6, 2014.

nationalarchives.gov.uk

webarchive.nationalarchives.gov.uk

"Zopiclone overdose". MHRA. Medicines and Healthcare Products Regulatory Agency. Archived from the original on December 6, 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (December 2012). "Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration". BMJ. 345: e8343. doi:10.1136/bmj.e8343. PMC 3544552. PMID 23248080.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Tariq SH, Pulisetty S (February 2008). "Pharmacotherapy for insomnia". Clinics in Geriatric Medicine. 24 (1): 93–105, vii. doi:10.1016/j.cger.2007.08.009. PMID 18035234.
American Geriatrics Society 2015 Beers Criteria Update Expert Panel (November 2015). "American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults". Journal of the American Geriatrics Society. 63 (11): 2227–2246. doi:10.1111/jgs.13702. PMID 26446832. S2CID 38797655.{{cite journal}}: CS1 maint: numeric names: authors list (link)
Bain KT (June 2006). "Management of chronic insomnia in elderly persons". The American Journal of Geriatric Pharmacotherapy. 4 (2): 168–192. doi:10.1016/j.amjopharm.2006.06.006. PMID 16860264.
Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE (August 2009). "Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem". Journal of Clinical Sleep Medicine. 5 (4): 377–383. doi:10.5664/jcsm.27552. PMC 2725260. PMID 19968019.
Kripke DF (February 2016). "Mortality Risk of Hypnotics: Strengths and Limits of Evidence" (PDF). Drug Safety. 39 (2): 93–107. doi:10.1007/s40264-015-0362-0. PMID 26563222. S2CID 7946506.
Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE (August 2009). "Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem". Journal of Clinical Sleep Medicine. 5 (4): 377–383. doi:10.5664/jcsm.27552. PMC 2725260. PMID 19968019.
Brielmaier BD (January 2006). "Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent". Proceedings. 19 (1): 54–59. doi:10.1080/08998280.2006.11928127. PMC 1325284. PMID 16424933.
Forrester MB (October 2007). "Eszopiclone ingestions reported to Texas poison control centers, 2005 2006". Human & Experimental Toxicology. 26 (10): 795–800. Bibcode:2007HETox..26..795F. doi:10.1177/0960327107084045. PMID 18025051. S2CID 25102558.
Jufe GS (July–August 2007). "[New hypnotics: perspectives from sleep physiology]". Vertex. 18 (74): 294–299. PMID 18265473.
Halas CJ (January 2006). "Eszopiclone". American Journal of Health-System Pharmacy. 63 (1): 41–48. doi:10.2146/ajhp050357. PMID 16373464.
Najib J (April 2006). "Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia". Clinical Therapeutics. 28 (4): 491–516. doi:10.1016/j.clinthera.2006.04.014. PMID 16750462.
Morinan A, Keaney F (December 2010). "Long-term misuse of zopiclone in an alcohol dependent woman with a history of anorexia nervosa: a case report". Journal of Medical Case Reports. 4 (1): 403. doi:10.1186/1752-1947-4-403. PMC 3014964. PMID 21143957.
Schwartz LM, Woloshin S (October 2009). "Lost in transmission--FDA drug information that never reaches clinicians". The New England Journal of Medicine. 361 (18): 1717–1720. doi:10.1056/NEJMp0907708. PMID 19846841.

ncbi.nlm.nih.gov

Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN (December 2012). "Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration". BMJ. 345: e8343. doi:10.1136/bmj.e8343. PMC 3544552. PMID 23248080.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M (October 2018). "Eszopiclone for insomnia". The Cochrane Database of Systematic Reviews. 2018 (10): CD010703. doi:10.1002/14651858.CD010703.pub2. PMC 6492503. PMID 30303519.
Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE (August 2009). "Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem". Journal of Clinical Sleep Medicine. 5 (4): 377–383. doi:10.5664/jcsm.27552. PMC 2725260. PMID 19968019.
Joya FL, Kripke DF, Loving RT, Dawson A, Kline LE (August 2009). "Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem". Journal of Clinical Sleep Medicine. 5 (4): 377–383. doi:10.5664/jcsm.27552. PMC 2725260. PMID 19968019.
Brielmaier BD (January 2006). "Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent". Proceedings. 19 (1): 54–59. doi:10.1080/08998280.2006.11928127. PMC 1325284. PMID 16424933.
Morinan A, Keaney F (December 2010). "Long-term misuse of zopiclone in an alcohol dependent woman with a history of anorexia nervosa: a case report". Journal of Medical Case Reports. 4 (1): 403. doi:10.1186/1752-1947-4-403. PMC 3014964. PMID 21143957.

dailymed.nlm.nih.gov

"Lunesta- eszopiclone tablet, coated". DailyMed. 24 May 2023. Retrieved 7 July 2023.

rxlist.com

Rxlist (26 October 2016). "Lunesta". Archived from the original on 5 December 2008. Retrieved 15 April 2017.

semanticscholar.org

api.semanticscholar.org

American Geriatrics Society 2015 Beers Criteria Update Expert Panel (November 2015). "American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults". Journal of the American Geriatrics Society. 63 (11): 2227–2246. doi:10.1111/jgs.13702. PMID 26446832. S2CID 38797655.{{cite journal}}: CS1 maint: numeric names: authors list (link)
Kripke DF (February 2016). "Mortality Risk of Hypnotics: Strengths and Limits of Evidence" (PDF). Drug Safety. 39 (2): 93–107. doi:10.1007/s40264-015-0362-0. PMID 26563222. S2CID 7946506.
Forrester MB (October 2007). "Eszopiclone ingestions reported to Texas poison control centers, 2005 2006". Human & Experimental Toxicology. 26 (10): 795–800. Bibcode:2007HETox..26..795F. doi:10.1177/0960327107084045. PMID 18025051. S2CID 25102558.

twobirds.com

Smillie M (23 April 2010). "Data exclusivity and definition of a new active substance: suspension of generic escitalopram-containing medicines by CHMP". Bird and Bird Commercial Law. Archived from the original on 23 May 2010.

web.archive.org

Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
"Eszopiclone" (PDF). F.A. Davis. 2017. Archived from the original (PDF) on October 8, 2017. Retrieved April 15, 2017.
Rxlist (26 October 2016). "Lunesta". Archived from the original on 5 December 2008. Retrieved 15 April 2017.
"GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia". Archived from the original on December 27, 2010.
"Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone)". European Medicines Agency. 15 May 2009. Archived from the original on 1 December 2017.
Smillie M (23 April 2010). "Data exclusivity and definition of a new active substance: suspension of generic escitalopram-containing medicines by CHMP". Bird and Bird Commercial Law. Archived from the original on 23 May 2010.